Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Boston Scientific Corporation    BSX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Goldberg Law PC Announces an Investigation of Boston Scientific Corporation and Advises Investors with Losses to Contact the Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/24/2017 | 05:16pm CET

Goldberg Law PC announces that it is investigating Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) concerning possible violations of federal securities laws.

If you purchased or otherwise acquired Boston Scientific shares and would like more information regarding the investigation, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

On February 23, 2017, Boston Scientific revealed it would be recalling its range of Lotus Valve heart devices, due to reports of an early release of a pin connecting the heart valve device to the delivery system.

Boston Scientific attributes the problem to "excess tension in the pin mechanism introduced during the manufacturing process."

When this information was revealed to investors, the value of Boston Scientific fell, causing investors harm.

If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BOSTON SCIENTIFIC CORPORAT
02/24 Goldberg Law PC Announces an Investigation of Boston Scientific Corporation a..
02/24 GLANCY PRONGAY & MURRAY LLP : Commences Investigation on Behalf of Boston Scient..
02/24 BOSTON SCIENTIFIC : Hospital first in UK to fit heart implant
02/24 BOSTON SCIENTIFIC : New Cross first to fit heart implant
02/24 BOSTON SCIENTIFIC : to Participate in 2017 RBC Capital Markets Global Healthcare..
02/24 Khang & Khang LLP Announces an Investigation of Boston Scientific Corporation..
02/23 Law Offices of Howard G. Smith Commences Investigation on Behalf of Boston Sc..
02/23 SQUARE : Boston Scientific and Hormel skid; Square and HP jump
02/23 BOSTON SCIENTIFIC : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
02/23 Lundin Law PC Announces an Investigation of Boston Scientific Corporation and..
More news
Sector news : Advanced Medical Equipment & Technology - NEC
02/09 Infineon, Cree warn U.S. might block Wolfspeed deal
02/02 EU probes online sales in electronics, video games, hotels
01/31DJTHERMO FISHER SCIENTIFIC : Earnings, Sales Rise
01/31DJDANAHER : Revenue, Profit Rise
01/30DJEUROPEAN MORNING BRIEFING : Corporate Events
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
02/23 Boston Sci's pain is Edwards' gain; shares ahead 3%
02/23 Boston Scientific recalls Lotus Valves due to possible manufacturing defect; ..
02/23 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
02/22 Symetis Follows Its Fellows Into Mitral Valve Technology
02/21 Tracking David Tepper's Appaloosa Management Portfolio - Q4 2016 Update
Advertisement
Financials ($)
Sales 2017 8 782 M
EBIT 2017 2 031 M
Net income 2017 1 339 M
Debt 2017 2 817 M
Yield 2017 -
P/E ratio 2017 26,49
P/E ratio 2018 20,89
EV / Sales 2017 4,16x
EV / Sales 2018 3,81x
Capitalization 33 742 M
More Financials
Chart BOSTON SCIENTIFIC CORPORAT
Duration : Period :
Boston Scientific Corporat Technical Analysis Chart | BSX | US1011371077 | 4-Traders
Full-screen chart
Technical analysis trends BOSTON SCIENTIFIC...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 28,1 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael F. Mahoney Chairman, President & Chief Executive Officer
Edward Mackey Executive Vice President-Operations
Daniel J. Brennan Chief Financial Officer & Executive Vice President
Keith D. Dawkins Global Chief Medical Officer & Executive VP
Nelda J. Connors Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BOSTON SCIENTIFIC CORP..13.18%33 742
THERMO FISHER SCIENTIF..12.49%62 801
DANAHER CORPORATION9.37%59 542
INTUITIVE SURGICAL, IN..15.95%28 581
PHILIPS-3.22%27 440
ILLUMINA, INC.25.75%23 408
More Results